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Abstract 
The aim of this review is to analyse the effectiveness of exogenous kisspeptin administration 
as a novel alternative of triggering oocyte maturation, instead of currently used triggers such 
as human chorionic gonadotrophin (hCG) or gonadotrophin releasing hormone (GnRH) 
agonist, in women undergoing in vitro fertilisation (IVF) treatment. Kisspeptin has been 
considered a master regulator of two modes of GnRH and hence gonadotrophin secretion, 
pulses and surges. Administration of kisspeptin-10 and kisspeptin-54 induces the luteinizing 
hormone (LH) surge required for egg maturation and ovulation in animal investigations and 
LH release during the preovulatory phase of the menstrual cycle and hypothalamic 
amenorrhoea in humans. Exogenous kisspeptin-54 has been successfully administered as a 
promising method of triggering oocyte maturation, following ovarian stimulation with 
gonadotrophins and GnRH antagonists in women undergoing IVF, due to its efficacy 
considering achieved pregnancy rates compared to hCG and GnRH agonists. Also, its safety 
in patients at high risk of developing ovarian hyperstimulation syndrome is noteworthy. 
Nevertheless,  further studies would be desirable to establish the optimal trigger of egg 
maturation and to improve the reproductive outcome for women undergoing IVF treatment. 
Keywords: kisspeptin, physiological mechanisms, exogenous administration, oocyte 
maturation trigger, IVF 
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The role of kisspeptins in reproduction 
The aim of the paper is to analyse the role of kisspeptins in reproduction as well as current  
modalities of treatment infertility. Kisspeptin is a polypeptide hormone, a product of the 
kisspeptin gene and its receptor, which plays a crucial role in the regulation of reproduction. 
Despite the fact that gonadotrophin releasing hormone (GnRH) has been considered to play a 
pivotal role in controlling reproductive functions, a hypothalamic neuropeptide kisspeptin, has 
recently emerged as a key regulator of the hypothalamo-pituitary-gonadal (HPG) axis, which 
plays a major role in the regulation of GnRH neurons. Kisspeptin has been considered a 
master regulator of two modes of GnRH and hence gonadotrophin secretion, pulses and 
surges. Although direct actions of kisspeptins on GnRH neurons are dominant, current data 
argue against a unimodal mechanism of action, because  such primary effects of kisspeptins 
appear to be insufficient to attain fertility. Owing to more recent investigations it appears that 
GnRH pulse and surge activity is a product of the integration of multiple signals, because 
kisspeptin pathways may also be mediated indirectly by other central regulators of GnRH 
neurons including neurokinin B, dynorphin A, supstance P, cocaine, amphetamine, gamma-
aminobutyric acid -glutamate and nitric oxide. In contrast to the intra-hypothalamic roles of 
kisspeptin as a master regulator of reproductive functions generating GnRH pulses and surges, 
less is known about the physiological significance of kisspeptins in other tissues such as, the 
human placenta, pancreatic islet cells, aorta and coronary vessels, umbilical vessels, and a 
number of brain cells types. Although kisspeptin primarily operates centrally to regulate the 
HPG axis, peripheral administration of different isoforms (kisspeptin-10 and kisspeptin-
54) has been shown to stimulate GnRH and gonadotrophin release. Since recently potential 
therapeutic applications of kisspeptins justified its use in clinical parctice for treatment of 
infertility such as novel oocyte maturation triggers in in vitro fertilisation (IVF), in prevention 
of ovarian hyperstimulation syndrome and prediction of ovulation. Exogenous kisspeptin-54 
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has been successfully administered as a promising method of triggering oocyte maturation, 
following ovarian stimulation with gonadotrophins and GnRH antagonists in women 
undergoing IVF, due to its efficacy considering achieved pregnancy rates compared to human 
chorionic gonadotrophin (hCG)  and GnRH agonists. Also, its safety in patients at high risk of 
developing ovarian hyperstimulation syndrome is noteworthy. Since kisspeptin levels are 
positively correlated to estradiol levels, increase kisspeptin surge in serum and urine may be 
used as a marker for dominant follicle development and pre-ovulation.  Nevertheless,  further 
research with larger studies would be desirable in the future to improve the reproductive 
outcome. 
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Introduction 
Since the early days of in vitro fertilisation (IVF), human chorionic gonadotrophin (hCG) has 
been used as the gold standard for triggering final oocyte maturation instead of the natural 
midcycle luteinizing hormone (LH) surge [1]. During the 1990's it became possible to trigger 
oocyte maturation with a single bolus of a gonadotrophin-releasing hormone (GnRH) agonist 
as an alternative to hCG, when the third generation GnRH antagonist was introduced in 
ovarian stimulation protocols. The induction of final follicular maturation using GnRH 
agonists offers potential advantages over hCG, because its triggering elicits a surge of 
gonadotrophins resembling the natural midcycle gonadotrophin surge, resulting in the 
retrieval of more mature oocytes and a significant reduction in ovarian hyperstimulation 
syndrome (OHSS) cases  [2].  
Despite the fact that GnRH plays a pivotal role in controlling reproductive functions, a 
hypothalamic neuropeptide kisspeptin, has recently emerged as a key regulator of the 
hypothalamo-pituitary-gonadal (HPG) axis, which plays a major role in the regulation of 
GnRH neurons. However, GnRH pulsatility is a product of the integration of multiple signals 
from other central regulators. Two other neuropeptides, neurokinin B and dynorphin A, which 
have come under the spotlight recently for their role in the regulation of GnRH pulse 
generation, are thought to be co-secreted with kisspeptin [3]. Following paracrine stimulatory 
and inhibitory inputs from neurokinin B and dynorphin A, kisspeptin directly signals GnRH 
neurons to release GnRH, which in turn stimulates the secretion of LH and follicle stimulating 
hormone (FSH).  In addition, kisspeptin mediates the negative and positive gonadal steroid 
feedback loop as well as adult fertility, controls the onset of puberty, relays information 
regarding the body's energy stores and serves as a vital link between the reproduction and 
energy homeostasis of the body [4]. In contrast to the intra-hypothalamic roles of kisspeptin 
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as a master regulator of reproductive functions generating GnRH pulses and surges, less is 
known about the physiological significance of kisspeptins in other tissues such as, the human 
placenta, pancreatic islet cells, aorta and coronary vessels, umbilical vessels, and a number of 
brain cells types [5]. Furthermore, compelling evidence accumulated in the last few years, has 
revealed that kisspeptins have emerged as important gatekeepers of key aspects of 
reproductive maturation and function, from sexual differentiation of the brain and puberty 
onset to adult regulation of gonadotrophin secretion and the metabolic control of fertility [6].  
Although kisspeptin primarily operates centrally to regulate the HPG axis, peripheral 
administration of different isoforms (kisspeptin-10 and kisspeptin-54) has been shown to 
stimulate GnRH and gonadotrophin release and to activate the LH surge required for egg 
maturation and ovulation in animal studies [7,8].  These findings have 
been subsequently demonstrated in females with normal menstrual cycles and hypothalamic 
amenorrhoea, with increments in plasma LH and FSH in the preovulatory phase [9-13].  Since 
data from investigations of animal and human studies has suggested that the peripheral 
administration of kisspeptin-10 and kisspeptin-54 is involved in the generation of the LH 
surge, it was hypothesized that exogenous kisspeptin could be used to trigger egg maturation 
in women with subfertility undergoing IVF treatment. According to the initial results from a 
recently published study, a subcutaneous bolus of kisspeptin-54 has been used to trigger 
oocyte maturation effectively in place of hCG in a FSH/GnRH antagonist IVF protocol. It 
seems that kisspeptin offers a novel alternative to trigger oocyte maturation in IVF treatment, 
evidenced by high rates of oocyte maturation in women with normal ovarian reserve [14]. 
Furthermore, kisspeptin-54 may be used as a promising approach to effectively and safely 
trigger oocyte maturation in women undergoing IVF treatment at high risk of developing 
OHSS [15]. The aim of this review is to analyse the effectiveness of exogenous kissppetin as 
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a new alternative for triggering oocyte maturation following ovarian stimulation for IVF 
treatment.       
 
Kisspeptin actions in the regulation of GnRH activity 
KISS1, the gene encoding kisspeptins, was originally identified in 1996 as a novel human 
malignant melanoma metastasis-supressor gene, whose expression might supress malignant 
melanoma cells [16]. The kisspeptin receptor, a member of the rhodopsin family of G-protein 
coupled receptors, was discovered in 1999, originally designated GPR54 and later termed 
KISS1R, has been demonstrated in various tissues, including the placenta, brain, pituitary, 
gonads, liver, pancreas, intestines, aorta, coronary artery and umbilical vein [17,18]. Three 
surrogate agonist peptides were isolated later from the placenta extracts in 2001, 
which were originally called metastin (a 54 amino acid protein), for its ability to inhibit 
cancer metastasis or kisspeptins (54, 14, and 13 amino acid peptides). The initial human 
kisspeptin precursor (prepro-kisspeptin), a 145-amino-acid protein, is cleaved to a 54 amino 
acid protein (the most abundant kisspeptin in human circulation with a half-life of 28 minutes) 
and to several other smaller peptide fragments, including 14, 13, and 10 amino acid peptides, 
which are collectively named kisspeptins. Two of them, kisspeptin-10 and kissppetin-54 
isoforms, have been used by exogenous administration to probe the potential clinical 
applications of kisspeptin. The kisspeptins numbers correspond to the number of amino acids. 
Kisspeptin-10 shares the common C-terminal decapeptid sequence, which leads to the strong 
binding with their receptors. The C-terminal part of the peptides is responsible for the high 
affinity binding and the activation of the kisspeptin receptor, because kisspeptin-54, -14, and -
13 as well as kisspeptin-10 have the same affinity, efficacy and biological activity at the level 
of KISS1R. There is a consensus that kisspeptin is a direct trigger of GnRH secretion in 
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mammals, which plays a major role in regulating GnRH neurons by activation of its native 
KISS1R expressed on the cell body/proximal dendrites of most GnRH neurons [3,19-22]. The 
hypothesis that kisspeptin neurons regulate GnRH secretion through the activation of the 
KISS1R on the plasma membrane of GnRH neurons has been confirmed experimentally, 
because selective elimination of the receptor from GnRH cells induces a hypogonadal 
phenotype [23]. The localisation of the majority of kisspeptin cell bodies in humans has been 
demonstrated in the infundibular (arcuate) nucleus in close apposition with GnRH neurons in 
the hypothalamus, and a second dense population of kisspeptin cells in the preoptic 
(anteroventral periventricular) area. Kisspeptin is produced by the axons which forming dense 
pericapillary plexuses in the infundibular stalk, the site of GnRH neurosecretion, where 
kisspeptin and GnRH neuronal networks are in close proximity via axo-somatic, axo-dendritic 
and axo-axonal contacts [24].   
Although the mechanisms by which kisspeptins directly regulate GnRH secretion are 
not absolutely clear, it has been demonstrated in various species that the translocation of 
kisspeptin along the phospholipid bilayer toward its receptor can evoke very potent 
depolarisation in GnRH neurons with increases in intracellular calcium and induction of the 
release of GnRH. The main signaling pathway involves Gq proteins and the activation of 
phospholipase C, MAP kinase phosphorylation via protein kinase C and mobilisation of 
calcium in the endoplasmic reticulum via phosphatidylinositol-3-kinase. In addition, the 
adenylate cyclase protein kinase A signaling pathway involving Gs proteins can also be 
activated, leading to a rise in extracellular calcium influx. Kisspeptin depolarises and excites 
GnRH neurons primarily through the activation of transient canonical receptor potential 
channels and the inhibition of K+ channels. [6,25]. The activation of the KISS1R results in a 
biphasic release of intracellular calcium, a rapid increase followed by a more sustained 
second-phase calcium response. The slower phase is maintained by kisspeptin receptor 
 9 
trafficking involving internalisation, recycling and recruitment from an intracellular pool, to 
prevent desensitisation following an initial acute phase [26]. Although direct actions of 
kisspeptins on GnRH neurons are dominant, current data argue against a unimodal mechanism 
of action, because  such primary effects of kisspeptins appear to be insufficient to attain 
fertility. Moreover, GnRH pulsatility is a product of the integration of multiple signals, 
because kisspeptin pathways may also be mediated indirectly by other central regulators of 
GnRH neurons. Regulators that appear to be of particular importance include members of the 
tachykinin peptide family, neurokinin B, substance P and neuropeptide A [27,28].  
Recently neurokinin B and the endogenous opioid dynorphin A have been 
demonstrated across a range of species from rodents to humans in the infundibular/arcuate 
nucleus due to frequent co-localisation of kisspeptin and neurokinin B neurons. It is becoming 
increasingly apparent that kisspeptin, co-secreted with neurokinin B and dynorphin (KNDy 
neuropeptides), regulates the GnRH pulse generation, as key hypothalamic regulators (KNDy 
hypothesis) in response to dynamic changes in steroid hormone concentrations, because most 
kisspeptin neurons express the ERα.  [3,29]. According to the evidence for KNDy model in 
the ewe, it is widely accepted that KNDy neurons may represent the long-sought GnRH pulse 
generator responsible for driving synchronous release of GnRH and gonadotrophins. An 
increase in endogenous neurokinin B initiates a positive feedback loop and each GnRH pulse 
by the activation of the neurokinin-3 receptor (NK3R) within KNDy neurons, to release 
kisspeptin onto GnRH neurons. However, dynorphin A, stimulated from the same neurons by 
neurokinin B, inhibits GnRH pulse frequency and terminates GnRH pulses acting directly on 
KNDy neurons. Thus, neurokinin B and dynorphin A control a the synchronised activity of 
KNDy neurons and kisspeptin solely activates GnRH neurons to regulate pulsatile GnRH 
secretion (Fig.1) [30]. Nevertheless, the role of neurokinin B in GnRH pulse regulation 
remains controversial because its effects have been more variable, with some studies in 
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rodents showing stimulatory or inhibitory effects on gonadotrophins. It is now clear that sex 
steroid milieu, pubertal status, and gender are important factors governing the effects of 
neurokinin B on gonadotrophin release [31]. Moreover, co-localisation of the NK3R in 
neurokinin neurons of the arcuate nucleus and the lack of the NK3R in GnRH neurons suggest 
that the actions of neurokinin B on GnRH neurosecretory activity in the ewe may be mediated 
indirectly via other neurones and neuropeptides [32]. Aiming to investigate the KNDy 
hypothesis in humans by assessing for the first time the effects of coadministration of 
kisspeptin-54, neurokinin B, and an opioid receptor antagonist, naltrexone, the results 
confirmed significant interactions between the KNDy neuropeptides on LH pulsatility and 
gonadotrophin release [33]. However, KNDy neurons may serve as a major target in the 
positive feedback actions of estradiol and might also be involved in the preovulatory 
GnRH/LH surge generation, in addition to the mode of the GnRH pulse generator under 
the negative feedback action of oestrogen [29]. Despite the widely reported role of kisspeptin 
neurons in the preoptic area mediating the positive feedback action of oestrogen as a trigger of 
the preovulatory GnRH/LH surge, a recent study reports that both  anteroventral 
periventricular and arcuate kisspeptins may be important in the generation of GnRH/LH 
surges in rats [5, 34]. It appears that anteroventral periventricular/periventricular preoptic 
nucleus (AVPV/PeN) kisspeptin neurons play a critical role in induction of GnRH/LH surge 
in female mice, because 17β-Estradiol increases the persistent sodium current and excitability 
of the kisspeptin neurons, dramatically altering their firing activity. Consequently. 
AVPV/PeN kisspeptin neurons generate spontaneous and repetitive burst firing, which is 
required for the high-frequency-stimulated release of kisspeptin for exciting GnRH neurons 
and potentially generating the GnRH surge [35]. 
In search of additional neuropeptides in kisspeptin and neurokinin B neurons in the 
infundibulum of postmenopausal women, co-localisation experiments have provided evidence 
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of the presence of the anorectic hypothalamic peptide cocaine- and amphetamine-regulated 
transcript in contacts with other peptidergic cells, including GnRH-IR neurons [36]. Under 
some circumstances, kisspeptin may also exert indirect actions on GnRH neurons with both 
gamma-aminobutyric acid (GABA)-glutamate and nitric oxide (NO) signalling being 
modified in the vicinity of the GnRH neuron cell bodies. Selective activation of GABA(A) 
receptors decreased kisspeptin-induced gonadotrophin secretion, whereas their blockade 
elicited robust LH and FSH bursts and protracted responses to kisspeptin-10 when combined 
with GABA(B) receptor inhibition. It seems that NO is also involved in the control of GnRH 
release because LH responses to kisspeptin-10 were protracted after inhibition of NO 
synthesis [37]. Furthermore, the gonadal steroid 17β-estradiol which conveys vital feedback 
information, has recently been demonstrated to modulate the excitability of kisspeptin as well 
as GnRH neurons by altering the expression and/or function of channel transcripts that 
orchestrate the downstream signalling of kisspeptin in GnRH neurons  [38]. Since kisspeptin 
cells and their KISS1R have been demonstrated throughout the brain in addition to the GnRH 
neurons, it may be that kisspeptin is involved in regulating the activity of multiple neuronal 
circuits in other brain regions. Therefore, it is becoming increasingly likely that kisspeptin 
acts as a neuromodulator through the KISS1R within multiple different neuronal networks in 
the brain, but also exhibits neuromodulatory actions typical of other neuropeptides through 
other RF amide receptors such as the neuropeptide FF receptors [39].    
 
Exogenous kisspeptin – a novel ovulation trigger  
Although kisspeptin primarily operates at central levels as a master regulator of GnRH pulse 
generation and secretion of gonadotrophins [3-5], the initial use of kisspeptins by  peripheral 
administration in animal experiments demonstrated that metastatin and kisspeptin-10 
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successfully induce the release of gonadotrophins and ovulation via activation of the 
hypothalamic GnRH neurons [7,8]. Furthermore, investigations involving exogenous 
administration of the natural, unmodified peptide sequence of kisspeptin-10 and kisspeptin-54 
have subsequently been performed in females with normal menstrual cycles [11] and 
hypothalamic amenorrhoea [13], using various doses and routes of delivery with no adverse 
effects having been reported. According to these findings, kisspeptin most potently induces 
gonadotrophin release during the preovulatory phase of the menstrual cycle, followed by the 
luteal phase, and then the follicular phase [9,10]. An elevation of plasma kisspeptin with 
consequent LH release has been suggested as a novel mechanism for manipulation of the 
HPG axis in women. Kisspeptin has been identified as a new therapeutic agent who may show 
potential for the treatment of reproductive disordes in the future [9-13]. Although a single 
subcutaneous bolus  injection of kisspeptin-54 temporarily increases the number of LH pulses 
in healthy women,  further studies would be advisable to investigate its therapeutic potential 
to restore LH pulsatility in cases with impaired GnRH secretion [12]. The mechanism by 
which kisspeptin stimulates the LH surge predominantly during the preovulatory phase may 
be explained by a potential role of estradiol-positive feedback on gonadotrophin secretion, 
because the plasma concentration of estradiol is greater in investigations with an LH surge 
compared to those without LH surges [40]. Since women with hypothalamic amenorrhoea  are 
more sensitive to kisspeptin than healthy women, kisspeptin is more likely to cause 
tachyphylaxis at higher doses. Nevertheless,  kisspeptin can persistently stimulate 
gonadotrophin secretion in women with hypothalamic amenorrhoea if the correct doses are 
chosen. During intravenous infusion of kisspeptin-54, the mean peak number of pulses was 3-
fold higher and the mean peak LH pulse secretory mass was 6-fold higher when compared to 
vehicle. Therefore, the determination of the dose range which kisspeptin-54 treatment 
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increases basal and pulsatile LH secretion in would represent a basis for studying the potential 
of kisspeptin-based therapies to treat women with hypothalamic amenorrhoea [13].  
Based on the data that exogenous kisspeptin may activate the LH surge required for 
egg maturation and ovulation in animal investigations [7,8] stimulate LH release in the 
preovulatory phase of the cycle [9,10] and hypothalamic amenorrhoea [13] in females, recent 
studies investigated the potential for kisspeptin as a novel method of triggering oocyte 
maturation in women undergoing IVF [14,15]. In a recent pilot study of 53 women 
undergoing a recombinant FSH plus GnRH antagonist IVF protocol a single subcutaneous 
injection of kisspeptin-54 was administered 24hrs after the last GnRH antagonist injection. 
Fertilisation occurred in 92% (49/53) of cases, with biochemical and clinical pregnancy rates 
of 40% (21/53) and 23% (12/53), respectively. In the 12 women achieving clinical 
pregnancies, eight women had singleton pregnancies and two women had twin pregnancies 
i.e. 12 babies, two further women having had miscarriages. The findings of the study suggest 
for the first time that kisspeptin-54 sufficiently triggers egg maturation to result in 
fertilisation, embryo implantation, and successful live birth in women with subfertility 
undergoing IVF therapy. Nevertheless, further studies would be required to estimate the 
clinical utility of kisspeptin-54 during IVF therapy when compared to established 
pharmacological triggers of egg maturation [14]. According to data from a later study, 
kisspeptin-54 may be a promising approach which can be used efficiently and safely to trigger 
egg maturation in women at high risk of developing OHSS while undergoing IVF treatment. 
In a randomised clinical trial of 60 women following a standard recombinant FSH/GnRH 
antagonist protocol, patients received a single injection of kisspeptin-54 to trigger oocyte 
maturation. The achieved pregnancy rates compared favourably with currently used 
pharmacological triggers of oocyte maturation. Oocyte maturation occurred in 95% of cases 
with biochemical pregnancy, clinical pregnancy, and live birth rates per transfer (n = 51) of 
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63, 53, and 45%, respectively, with no cases of clinically significant OHSS and adverse 
events associated with the kisspeptin-54 injection. Despite attractive results with the use of 
kisspeptin-54 to trigger oocyte maturation in women at high risk of OHSS undergoing IVF 
treatment, additional large randomised studies would be desirable to compare the efficacy and 
safety of kisspeptin-54 vs. currently used triggers to verify the optimal trigger of oocyte 
maturation [15]. In order to overcome the drawback of kisspeptin
'
s short half-life, a 
kisspeptin-10 analogue (compound 6, C6) has recently been synthesised, capable of triggering 
ovulation in ewes after a single intramuscular injection, although a longer half-life increases 
the chance of tachyphylaxis unless the doses are not appropriately reduced. Nevertheless, 
these results imply that kisspeptin-10 analogues opens up new possibilities for the treatment 
of reproductive disorders in humans and may find application in the management of livestock 
reproduction [41].   
 
Conclusions 
Peripheral kisspeptin administration could be used as a novel and promising method of 
triggering oocyte maturation in women undergoing IVF therapy due to its efficacy estimated 
through pregnancy rates when compared to pharmacological triggers currently in use. 
Furthermore, it is noteworthy that kisspeptin may also be administered  effectively and safely 
to trigger oocyte maturation  in patients at high risk of developing OHSS. Nevertheless, 
further research with larger studies will be required in the future to determine the clinical 
utility of kisspeptin, establish the optimal trigger of egg maturation, and to improve the 
reproductive outcome for women undergoing IVF treatment.   
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Fig.1. Schematic illustration of the GnRH pulse generator  
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